CARDIOVASCULAR BIOTHERAPEUTICS, INC. (OTCBB: CVBT)

Dear Reader:

CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT) is without a doubt one of the most intriguing and perhaps promising companies that we have covered.  Its CardioVascu-Grow™ product may provide new hope for those suffering with Cardiovascular disease - estimated at over 60 million people in the U.S. alone.  And the product may also be effective in other applications such as wound healing.  This would address the diabetic and elderly market - both of which would greatly benefit from an agent that could stimulate the growth of new blood vessels in the wound area.

Also, to review StockUpTicks profile on CVBT click here.
 

*BREAKING* News from CVBT

Press Release Source: CardioVascular BioTherapeutics, Inc.
Tuesday May 16, 9:30 am ET

LAS VEGAS--(BUSINESS WIRE)--May 16, 2006--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT - News) announced today that Mr. Daniel C. Montano, CEO of CardioVascular BioTherapeutics, Inc. (CVBT), has been invited to present CVBT's medical advances at the Dutton Associates' "Recognizing Opportunity" Health Sciences Small Cap Conference. The event, scheduled for Wednesday, May 31, 2006, at The St. Regis Hotel in San Francisco, is a unique opportunity for investment professionals to meet with approximately 15 of Dutton's top-rated health science companies and many of Dutton's senior analysts.

Source: CardioVascular BioTherapeutics, Inc. 

· View Multimedia Gallery

Mr. Montano stated, "Blood perfusion to tissues and organs through the growth of new blood vessels using CVBT's Cardio Vascu-Grow(TM) as the active ingredient in CVBT's drug candidates has great potential in treating cardiovascular disease, peripheral vascular disease, stroke, lumbar eschemia, diabetic wound healing, and other diseases that could be effectively treated by increased blood flow. This event allows me the opportunity to speak directly with interested institutions and investment professionals about our company, the progress we have made to date in the field of angiogenesis, and the exciting future of CVBT."

Dutton Associates is one of the largest issuer-paid equity research firms in the United States and its investment performance is ranked comparable to that of the top Wall Street firms. Its analysts, primarily CFAs with over 20 years of experience at the major securities firms, are among the most experienced on Wall Street. Dutton Associates offers high-quality, independent, fundamental research on small cap public companies.

CVBT is a biopharmaceutical company developing drug candidates with Cardio Vascu-Grow(TM) as the active ingredient for a number of diseases characterized by inadequate blood flow to a tissue or organ. Currently, the company is conducting two FDA-authorized clinical trials: one in the area of coronary artery disease in no-option heart patients, and one in the area of impaired wound healing seen in diabetics. Additionally, the company has completed pre-clinical studies in animal models of peripheral vascular disease of the legs and stroke recovery. Clinical trials in these two indications are planned to begin later this year in the U.S. A foreign clinical trial has been initiated in the area of chronic back pain, where blockage of arteries supplying the lower back have been implicated in this common ailment.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding our expectations for new research, our progress with clinical trials or our future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of our drug candidates, market acceptance of CardioVascular BioTherapeutics, Inc. products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Cardio Vascu-Grow(TM) is a trademark of CardioVascular BioTherapeutics, Inc.

MULTIMEDIA AVAILABLE:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5149776

Contact:

CardioVascular BioTherapeutics, Inc.
Investor Relations, 702-391-4999
investorrelations@cvbt.com

Source: CardioVascular BioTherapeutics, Inc.
 

About CardioVascular BioTherapeutics

In two separate clinical trials in Germany in the mid-1990s conducted by Dr. Thomas J. Stegmann, a protein identical in structure to Cardio Vascu-Grow™ prompted the growth of new blood vessels in the hearts and increased the pumping capacity of the hearts in the "no option" heart patients treated. 

CVBT is currently working to confirm the medical benefits of this protein drug candidate through human clinical trials authorized by the U.S. Food and Drug Administration (FDA). The FDA clinical trial for no-option heart patients commenced in August 2004, with a network of six major medical centers conducting the trial.  To date, 60 human no-option heart patients have been treated with Cardio Vascu-Grow™ and in Dr. Stegmann's German trial using a protein identical in structure to Cardio Vascu-Grow™.

CVBT recently announced that its Investigational New Drug Application ("IND") to the U.S. FDA had been allowed and the company is now authorized to commence its Phase I clinical trial in diabetic patients with foot ulcers and/or open leg wounds.  Wound healing requires angiogenesis for the healing process to occur, making this indication an attractive target for treatment with Cardio Vascu-Grow™.  In animal models, Cardio Vascu-Grow™ has been shown to be a potent stimulator of wound healing, almost doubling the rate at which a wound will heal.  People with diminished healing abilities, including diabetics and the elderly, could greatly benefit from an agent that could stimulate the growth of new blood vessels in the wounded area.  10 Million Patients Suffer from Diabetic Leg Ulcers, Bed Sores and Surgical Wounds.

CVBT is committed to conducting additional clinical trials to establish the positive effect of its drug candidate aimed at improving the quality of life for those suffering from heart disease, stroke, diabetic wounds, or peripheral vascular disease, and CVBT management pledges to continue exploration for additional applications of Cardio Vascu-Grow™.
 

The Need for Cardio Vascu-Grow™

• 38% of all deaths in the United States are caused by cardiovascular disease 
• 13.2 million suffer from coronary artery disease
• 4.8 million people in the U.S. have suffered strokes
• 7.8 million people in the U.S. will have a heart attack this year

Recent News From CVBT

Press Release 
Source: CardioVascular BioTherapeutics, Inc.
Wednesday April 26, 9:30 am ET

LAS VEGAS--(BUSINESS WIRE)--April 26, 2006--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT - News) today announced that it has signed a collaborative research and development agreement with the global clinical contract research organization, bioRASI, to initiate proof of concept clinical studies in patients suffering from chronic back pain. Chronic back pain, estimated in published reports to affect 26 million Americans, has recently been linked to blockage of blood vessels supplying the lower back, leading to a condition referred to as lumbar ischemia. The patients will receive CVBT's new drug candidate for lumbar ischemia which has Cardio Vascu-Grow(TM) as its active ingredient. The multi-site clinical study will be performed in Russia and Eastern Europe and will enroll patients who have proven blockages in their lumbar arteries which leads to poor perfusion and chronic pain in their lower backs.

Thomas J. Stegmann, M.D., co-founder and Chief Clinical Officer of CVBT stated, "Our new clinical collaboration with bioRASI in patients with blocked lumbar arteries is a natural extension of our ongoing clinical trials with no-option heart patients, who are receiving our drug candidate for advanced atherosclerotic disease of their coronary arteries. In Russia, we will be able to rapidly assess the potential efficacy of our drug candidate in this medical indication more economically than performing similar clinical trials in the United States. Cardiovascular disease results from a lack of proper blood perfusion and affects millions of patients. Whether it is coronary heart disease, vascular consequences of diabetes, stroke, or intestinal ischemia, it is becoming accepted now by the medical community that if you can increase blood flow to the affected tissues the patients' condition should improve. We want to find out if Cardio Vascu-Grow(TM) can accomplish this in patients with chronic back pain caused by blocked lumbar arteries."

To read the entire release and disclaimer, click here

Press Release 
Source: CardioVascular BioTherapeutics, Inc.
Wednesday March 22, 9:30 am ET

LAS VEGAS--(BUSINESS WIRE)--March 22, 2006--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT.OB - News), announced today it has successfully completed the sale in a private placement of $20,000,000 of senior secured notes together with warrants to purchase 705,882 shares of the Company's common stock.

Daniel C. Montano, CEO of the company, stated, "This funding should carry us through Phase II of our 'No Option' Heart Patient and Phase I and II of our Wound Healing clinical trials, and reduce our need for additional capital."

The notes are convertible at any time at $12 per share. In addition, the notes are convertible after five months from the closing date at 94% of the average of the preceding five days weighted average trading price, if the result is lower than $12 per share. Conversion of the senior secured notes into the Company's common stock is limited to no more than 10% of the original $20,000,000 note balance per month. The notes mature in March 2009, and bear a resetting floating interest rate of three month LIBOR plus 7%. The warrants may be exercised anytime up to the maturity of the notes. The warrant exercise price is $8.50 per share, which is based on 120% of the weighted average trading price of the ten trading days prior to closing. The notes are secured by substantially all of the company's assets. The full details of the transaction may be found in the agreements as filed with the Securities and Exchange Commission ("SEC") today.

CardioVascular BioTherapeutics, Inc. (Stock symbol:CVBT.OB) is a biopharmaceutical company focused on developing a new drug for the treatment of cardiovascular diseases where the growth of new blood vessels can improve the outcome for patients with these diseases. Its drug candidate, Cardio Vascu-Grow(TM), is designed to facilitate the growth of new blood vessels in the heart and other tissues with an impaired vascular system.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding our future revenues, cash usage and our cash flow breakeven point are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of Cardio Vascu-Grow(TM), market acceptance of CardioVascular BioTherapeutics, Inc. products by our customers, future revenues, future expenses, future margins, cash usage, and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Cardio Vascu-Grow(TM) is a trademark of CardioVascular BioTherapeutics, Inc.

Contact:
CardioVascular BioTherapeutics, Inc.
Investor Relations, 702-391-4999
investorrelations@cvbt.com
or
Investor Awareness, Inc.
Tony Schor, 847-945-2222
www.investorawareness.com

Source: CardioVascular BioTherapeutics, Inc.

Press Release 
Source: CardioVascular BioTherapeutics, Inc.
Friday February 24, 10:09 am ET

LAS VEGAS--(BUSINESS WIRE)--Feb. 24, 2006--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT.OB - News) announced today that a lecture delivered at the International Regenerative Medicine Foundation's 3rd annual conference held in Kauai, Hawaii has important implications for the development of its lead drug candidate, Cardio Vascu-Grow(TM). During that lecture, Dr. David Rollo, Chief Medical Officer of Philips Medical Systems, a company that develops, manufactures and markets advanced imaging equipment ("Philips"), spoke on the application of diagnostic imaging to assess the efficacy of FGF-1 for the diagnosis, treatment and management of ischemia. FGF-1 is the protein component of Cardio Vascu-Grow(TM).

Dr. Rollo's talk focused on Philips' recent development of imaging devices and related software that image molecular agents designed to specifically visualize, at high sensitivity, ischemic areas of the heart, brain and other tissues. Ischemia is poor blood perfusion due to blocked arteries. Dr. Rollo indicated that, as FGF-1 is a potent inducer of new blood vessel growth, new imaging agents could be utilized to first diagnose ischemic diseases then assess the effect of FGF-1 given to those patients. CVBT currently has two FDA-allowed clinical trials to treat ischemic diseases; the first in no-option heart patients; the second in ischemic leg disease, which leads to dermal ulcers that do not heal. A third trial in peripheral vascular disease is scheduled to start later this year.

To read the entire release and disclaimer, click here
a

Press Release 
Source: CardioVascular BioTherapeutics, Inc.
Thursday February 23, 9:22 am ET

LAS VEGAS--(BUSINESS WIRE)--Feb. 23, 2006--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT.OB - News) announced today that its Chief Operating and Scientific Officer, Jack Jacobs, Ph.D., presented the company's recent progress in its efforts to bring new therapeutics to the market for the treatment of stroke. His lecture was delivered on February 22, 2006 at the International Regenerative Medicine Foundation's 3rd annual conference entitled "New Science for a Better Medicine."

The lecture reviewed the promising data the company has collected to date to reduce the size of experimental strokes in animals. CVBT is developing human FGF-1, a protein which is a potent neuroprotective agent, as well as a stimulator of enhanced blood perfusion in the brain. In animals receiving an experimental stroke, the FGF-1 protein decreased the area of the stroke, resulting in a significant decrease in neurological deficits in these animals. The FGF-1 was administered to the animals up to 8 hours after the stroke was given, and a reduction in the stroke area and the number of neurological deficits was still observed, which, if it can be shown in humans, has potential clinical significance.

Dr. Jacobs also reviewed progress in a new initiative CVBT has launched in the area of stroke recovery. As human FGF-1 is a potent stimulator of new nerve growth, it has the potential to repopulate damaged areas of the brain with new neurons. Preclinical experiments with FGF-1 in animals with a chronic stroke condition indicated a significant increase in neuronal density in the areas affected by the stroke.

To read the entire release and disclaimer, click here
 

CVBT Leadership

a

Thomas J. Stegmann, M.D.

Dr. Thomas J. Stegmann’s discovery of ways to stimulate growth of new blood vessels in the human heart opens up an exciting new area of biotechnology and medical treatment for cardiovascular disease.  His research and subsequent trials have been articulated in an acclaimed volume, New Vessels for the Heart: Angiogenesis as New Treatment for Coronary Heart Disease: The Story of its Discovery and Development, published in 2005.

Dr. Stegmann is the cardiac surgeon who pioneered the procedure upon which CVBT was founded.   For the past 12 years, he has been working in the area of neo-angiogenesis and human growth factors, prompting a discovery that opens a new area of biotechnology and medical treatment for the treatment of cardiovascular disease. Besides various scientific publications, he has since authored New Vessels for the Heart, the story of his discovery and its development.

Since December 1984, Dr. Stegmann has held the position of Professor of Surgery and Director of the Department for Thoracic and Cardiovascular Surgery at the Fulda Medical Center in Germany, a major medical and teaching hospital serving the University of Marburg and the greater Frankfurt, Germany area. He is also a member of the faculty of Hannover Medical School in Germany. He received his medical degree (summa cum laude) from Heidelberg University, Heidelberg, Germany.

Daniel C. Montano brings a wide range of management experience to his roles, having served as CEO of 14 operating companies in industries such as real estate, high technology, medical technology, biotechnology, food products, financial institutions, and service companies.  From 1981 until 2004, Montano was a member of the Board of Directors of Helen of Troy, Ltd, a Texas company with revenue of over $450 million.  He also spent 30 years as an investment banker.  Montano received his MBA from the University of Southern California and his undergraduate degree from California State University, Los Angeles.
a a

Financial Highlights For CVBT

To Contact CVBT

---

*** The Bull is Running. ***
There may never be a better time to feature YOUR company
to over 1 MILLION investors.

To learn more about our programs email us directly at info@stockupticks.com

Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP).  The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness.  Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision.  MP has been paid twenty four thousand dollars by CardioVascular BioTherapeutics Inc. for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company.  Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 - Market Pathways 17595 Harvard Ave., Suite C519 Irvine, CA  92614.  MP is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement.  Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results.  The opinions contained herein reflect our current judgment and are subject to change without notice. MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned.  Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated.